Currently, confirmation of a clinical diagnosis of AD still requires post mortem identification of parenchymal amyloid beta (Aβ) deposits and intra-neuronal neurofibrillary tangles composed of abnormally phosphorylated tau protein [2-5] and severe loss of brain tissue [6-8]. The gene discussed is MAPT; the disease is Alzheimer disease.